Nanobots Therapeutics

nanobotstx.com ↗ ·Barcelona ·Seed

Nanobots Therapeutics is a Barcelona-based biotech spin-off of the Institute for Bioengineering of Catalonia (IBEC) and ICREA, founded in January 2023 out of Prof. Samuel Sánchez's Smart Nano-Bio Devices lab. It develops the MotionTx platform of self-propelled, enzyme-powered nanoparticles ('nanobots') that actively swim through tissue to improve drug penetration and accumulation in solid tumours, with lead candidate NBT-101 for non-muscle-invasive bladder cancer and NBT-102 for colorectal cancer. The company closed a €478,000 pre-seed in 2023 and a first ~€1M tranche of its seed round in December 2024; it is headquartered at Barcelona Science Park.

Founded

2023

Founders

Total funds raised

€2.4M

SectorsBiotech, Oncology, Nanotechnology, Drug Delivery, Deeptech Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Andrés G. Fernández

Co-Founder, Drug Development Advisor

Daniel Oliver

Co-Founder, Strategic Advisor

Also at Capital Cell

Gonzalo Fernández-Miranda

Co-Founder

Isaac Cabezas Baños

Co-Founder, Finance Advisor

Marc Ramis Castelltort

Co-Founder

Samuel Sánchez Ordóñez

Academic Founder, Interim CEO & CSO

Global models 4

Bionaut Labs

United States · bionautlabs.com ↗

Develops remotely actuated micro-robots that move through tissue to deliver drugs precisely to hard-to-reach disease sites, the same active drug-delivery platform model licensed or partnered with pharma.

~$70MComparable

Nanobiotix

France · www.nanobiotix.com ↗

Nanomedicine platform company whose injectable nanoparticles make solid-tumour treatment work better, built to reach the clinic and then license to or partner with big pharma (as it did with J&J).

~$60M (pre-IPO VC)Comparable

Robeauté

France · www.robeaute.com ↗

Builds self-navigating microrobots that travel through tissue to deliver therapies to targets deep in the body, a close match for a mobile-nanoparticle drug-delivery platform.

~$40MComparable

BIND Therapeutics

United States

Venture-backed nanoparticle platform (Accurins) built to raise drug build-up in solid tumours, with its own lead programmes plus pharma partnerships; it was later bought by Pfizer.

~$100M (pre-IPO VC)Comparable